PO.BCS01.05 · 生物信息与计算
R361H SMAD4突变对结直肠癌中TGF-β信号传导的结构和动力学影响
Structural and kinetic effects of R361H SMAD4 mutation on TGF-ß signaling in colorectal cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:SMAD4突变破坏结直肠癌中的TGF-β信号传导。我们聚焦于反复出现的MH2结构域R361H突变,其结构和相互作用效应仍不明确。利用结构建模、对接和分子动力学,我们评估了R361H如何改变SMAD4的稳定性及其与SMAD1/2/3/5的结合。
方法:从RCSB获取SMAD1-5的AlphaFold模型,并用PyMOL将R361H突变引入SMAD4。将野生型和突变型SMAD4分别用ClusPro与每个R-SMAD对接。所得复合物随后在GROMACS中进行修复、溶剂化和参数化。每个复合物运行100 ns的分子动力学模拟。使用GROMACS计算全局和结构域特异性的RMSD/RMSF。使用MMPBSA.py计算结合能和每个残基的贡献。
结果:R361H突变以伴侣特异性方式改变了SMAD4-R-SMAD复合物的稳定性。在复合物水平上,SMAD4-SMAD1和SMAD4-SMAD3的总体RMSD仅显示出微小变化(Δcomplex ≈ SMAD1为−0.05 nm,SMAD3为+0.07 nm,MUT − WT)。相比之下,SMAD4-SMAD2和SMAD4-SMAD5明显失稳,RMSD偏移大得多(Δcomplex分别≈+0.34和+0.50 nm)。在所有四个复合物中,突变体中的R-SMAD连接区变得更加柔性(+0.10—0.34 nm),而SMAD4 MH2的活动性在SMAD1、SMAD3和SMAD5复合物中增加。RMSF分析将这些变化定位于SMAD4残基约470—490和540—550,以及每个R-SMAD中的伴侣特异性区域。能量分解揭示了每个伴侣的不同机制。在SMAD1-SMAD4复合物中,野生型和突变型中强相互作用的残基重叠最小;PyMOL比对(RMSD ≈ 36 Å)和对接分值表明,R361H驱动一种替代性的、重塑的结合模式,而非单纯削弱野生型界面。在SMAD2-SMAD4复合物中,一个疏水到极性的补丁相互作用(SMAD4 274-281,SMAD2 181-187)在突变体中变得不那么有利,这与SMAD4 RMSF增加和复合物RMSD升高相一致。在SMAD3-SMAD4复合物中,一个关键的R420SMAD3-E417SMAD4盐桥在突变体中被削弱约3 kcal/mol。RMSF数据表明,在野生型中,柔性的C端尾部经常采取此相互作用所需的取向,而突变型尾部则以较不利的取向更加僵硬。在SMAD5-SMAD4复合物中,突变体在SMAD5残基185-188与SMAD4极性补丁(263-268)之间获得了有利接触,SMAD4 MH2活动性增加(约0.2 nm)。
结论:该框架提示R361H以伴侣特异性方式重塑SMAD4-R-SMAD界面,与SMAD1诱导显著重组,与SMAD2/3/5则产生更细微的变化。这些伴侣特异性界面可能代表可成药的表面,用于恢复肿瘤抑制性TGF-β响应,或在R361H突变型结直肠癌中选择性地约束促转移信号传导。
查看英文原文 English abstract
Introduction: SMAD4 mutations disrupt TGF-ß signaling in colorectal cancer. We focus on the recurrent MH2-domain R361H mutation, whose structural and interaction effects remain unclear. Using structural modeling, docking, and molecular dynamics, we assess how R361H alters SMAD4 stability and binding to SMAD1/2/3/5.
Methodology: AlphaFold models of SMAD1-5 were obtained from RCSB, and the R361H mutation was introduced to SMAD4 with PyMOL. Wildtype and mutant SMAD4 were docked separately to each R-SMAD with ClusPro. The resulting complexes were subsequently repaired, solvated, and parameterized in GROMACS. Molecular dynamics simulations were run for 100 ns per complex. Global and domain-specific RMSD/RMSF were computed with GROMACS. MMPBSA.py was used to calculate binding energies and per-residue contributions.
Results: R361H mutation altered SMAD4-R-SMAD complex stability in a partner-specific way. At the complex level, SMAD4-SMAD1 and SMAD4-SMAD3 showed only small changes in overall RMSD (Δcomplex ≈ −0.05 nm for SMAD1 and +0.07 nm for SMAD3, MUT - WT). In contrast, SMAD4-SMAD2 and SMAD4-SMAD5 were clearly destabilized, with much larger RMSD shifts (Δcomplex ≈ +0.34 and +0.50 nm, respectively).Across all four complexes, R-SMAD linkers became more flexible in the mutant (+0.10-0.34 nm) while SMAD4 MH2 mobility increased in the SMAD1, SMAD3, and SMAD5 complexes.RMSF analysis localized these changes to SMAD4 residues ~470-490 and 540-550 and to partner-specific regions in each R-SMAD.Energy decomposition revealed distinct mechanisms for each partner. In the SMAD1-SMAD4 complex, strongly interacting residues in wildtype and mutant showed minimal overlap; PyMOL alignment (RMSD ≈ 36 Å) and docking scores indicate that R361H drives an alternative, remodeled binding mode rather than simply weakening the wildtype interface. In the SMAD2-SMAD4 complex, a hydrophobic to polar patch interaction (SMAD4 274-281, SMAD2 181-187) becomes less favorable in the mutant, consistent with increased SMAD4 RMSF and higher complex RMSD. In the SMAD3-SMAD4 complex, a key R420SMAD3-E417SMAD4 salt bridge is weakened by ~3 kcal/mol in the mutant. RMSF data indicate that in the wildtype, a flexible C-terminal tail frequently adopts the orientation needed for this interaction, whereas the mutant tail is more rigid in a less favorable orientation. In the SMAD5-SMAD4 complex, the mutant gains favorable contacts between SMAD5 residues 185-188 and a polar SMAD4 patch (263-268), with increased SMAD4 MH2 mobility (~0.2 nm).
Conclusion: This framework suggests that R361H remodels SMAD4-R-SMAD interfaces in a partner-specific manner, inducing marked reorganization with SMAD1 and more nuanced shifts in SMAD2/3/5. These partner-specific interfaces may represent druggable surfaces for restoring tumor-suppressive TGF-ß responses or selectively constraining pro-metastatic signaling in R361H-mutant colorectal cancer.
利益披露 Disclosure
E. Boczko, None..
I. Silverman, None..
Y. Wiener, None..
R. Maitra, None.